|
Market Closed -
Nasdaq
16:00:00 2026-08-20 EDT
|
5-day change | 1st Jan Change | ||
| 53.69 USD | -1.29% |
|
+6.09% | +22.50% |
| 08-05 | Exelixis, Inc., Q2 2026 Earnings Call, Aug 05, 2026 | |
| 08-05 | (EXEL) Exelixis Now Expects Fiscal 2026 Revenue Range $2.50B-$2.55B, vs. FactSet Est of $2.60B | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 13.48B | |||||
| 72.21B | |||||
| 63.98B | |||||
| 28.53B | - | ||||
| 25.07B | |||||
| 28.42B | - |
- Stock Market
- Stocks
- EXEL Stock
- Charts Exelixis, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
